{"nctId":"NCT02202551","briefTitle":"Open-Label Safety Study of ADS-5102 in PD Patients With LID","startDateStruct":{"date":"2014-07"},"conditions":["Dyskinesia","Levodopa Induced Dyskinesia (LID)","Parkinson's Disease (PD)"],"count":223,"armGroups":[{"label":"ADS-5102","type":"EXPERIMENTAL","interventionNames":["Drug: ADS-5102"]}],"interventions":[{"name":"ADS-5102","otherNames":["amantadine HCl extended release"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed a current IRB/REB/IEC-approved informed consent form\n* Completed all study visits in previous Adamas efficacy study or were ineligible for participation in previous Adamas studies due to having undergone prior deep brain stimulation.\n* Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria\n* On a stable regimen of antiparkinson's medications at least 30 days prior to screening, including a levodopa preparation administered not less than three times daily.\n* History of peak dose dyskinesia that might benefit from specific dyskinesia treatment in the judgment of the subject and clinical investigator\n\nExclusion Criteria:\n\n* Discontinued ADS-5102 in previous Adamas efficacy study due to intolerable or unacceptable AEs considered to be related to ADS-5102\n* History of neurosurgical intervention related to Parkinson's disease, with the exception of deep brain stimulation\n* History of seizures since completion of participation in previous Adamas studies or within 2 years\n* History of stroke or TIA since completion of participation in previous Adamas studies or within 2 years\n* History of cancer since completion of participation in previous Adamas studies or within 2 years, with the following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer\n* Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening\n* If female is pregnant or lactating\n* If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment.\n* Treatment with an investigational drug (other than ADS-5102) or device within 30 days prior to screening\n* Treatment with an investigational biologic within 6 months prior to screening\n* Current or planned participation in another interventional clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Reported AEs and Safety-Related Study Drug Discontinuations","description":"The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (Parts I-III Combined Scores)","description":"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.\n\nPart I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).\n\nTotal range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.\n\nParts I, II, and III are summed to make the total score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8","spread":"18.43"},{"groupId":"OG001","value":"45.6","spread":"19.24"},{"groupId":"OG002","value":"52.8","spread":"23.06"},{"groupId":"OG003","value":"52.4","spread":"16.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"10.03"},{"groupId":"OG001","value":"-2.8","spread":"14.11"},{"groupId":"OG002","value":"0.8","spread":"12.00"},{"groupId":"OG003","value":"-5.3","spread":"10.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"13.41"},{"groupId":"OG001","value":"-1.4","spread":"16.22"},{"groupId":"OG002","value":"5.7","spread":"15.53"},{"groupId":"OG003","value":"-5.2","spread":"11.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"10.04"},{"groupId":"OG001","value":"1.5","spread":"12.49"},{"groupId":"OG002","value":"6.5","spread":"14.18"},{"groupId":"OG003","value":"-5.3","spread":"12.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"15.43"},{"groupId":"OG001","value":"-0.4","spread":"15.20"},{"groupId":"OG002","value":"1.6","spread":"18.29"},{"groupId":"OG003","value":"-4.8","spread":"12.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"16.78"},{"groupId":"OG001","value":"2.6","spread":"14.57"},{"groupId":"OG002","value":"6.1","spread":"18.34"},{"groupId":"OG003","value":"-4.6","spread":"15.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"14.83"},{"groupId":"OG001","value":"2.6","spread":"14.57"},{"groupId":"OG002","value":"6.1","spread":"18.34"},{"groupId":"OG003","value":"-4.6","spread":"15.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"19.58"},{"groupId":"OG001","value":"7.3","spread":"19.18"},{"groupId":"OG002","value":"9.4","spread":"19.10"},{"groupId":"OG003","value":"-4.9","spread":"13.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"16.65"},{"groupId":"OG001","value":"3.7","spread":"13.80"},{"groupId":"OG002","value":"6.4","spread":"22.65"},{"groupId":"OG003","value":"0.9","spread":"16.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"15.66"},{"groupId":"OG001","value":"3.7","spread":"15.29"},{"groupId":"OG002","value":"6.5","spread":"16.46"},{"groupId":"OG003","value":"4.1","spread":"17.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale MDS-UPDRS (Part IV - Motor Complications)","description":"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.\n\nGenerally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"3.38"},{"groupId":"OG001","value":"9.6","spread":"3.07"},{"groupId":"OG002","value":"9.8","spread":"3.92"},{"groupId":"OG003","value":"10.4","spread":"2.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"3.21"},{"groupId":"OG001","value":"-3.4","spread":"3.27"},{"groupId":"OG002","value":"-3.6","spread":"4.16"},{"groupId":"OG003","value":"-4.0","spread":"4.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"3.61"},{"groupId":"OG001","value":"-3.2","spread":"3.61"},{"groupId":"OG002","value":"-1.1","spread":"5.03"},{"groupId":"OG003","value":"-3.9","spread":"3.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"3.61"},{"groupId":"OG001","value":"-3.3","spread":"3.12"},{"groupId":"OG002","value":"-1.4","spread":"3.84"},{"groupId":"OG003","value":"-4.4","spread":"3.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"3.95"},{"groupId":"OG001","value":"-2.8","spread":"3.39"},{"groupId":"OG002","value":"-2.9","spread":"4.81"},{"groupId":"OG003","value":"-4.7","spread":"4.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"3.64"},{"groupId":"OG001","value":"-2.9","spread":"3.56"},{"groupId":"OG002","value":"-2.5","spread":"4.40"},{"groupId":"OG003","value":"-3.6","spread":"3.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"3.82"},{"groupId":"OG001","value":"-3.3","spread":"3.42"},{"groupId":"OG002","value":"-1.9","spread":"4.32"},{"groupId":"OG003","value":"-2.5","spread":"4.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"4.20"},{"groupId":"OG001","value":"-2.9","spread":"3.67"},{"groupId":"OG002","value":"-2.7","spread":"3.90"},{"groupId":"OG003","value":"-3.7","spread":"3.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"3.77"},{"groupId":"OG001","value":"-2.8","spread":"3.60"},{"groupId":"OG002","value":"-3.7","spread":"4.69"},{"groupId":"OG003","value":"-4.3","spread":"3.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"3.28"},{"groupId":"OG001","value":"-2.4","spread":"4.19"},{"groupId":"OG002","value":"-3.6","spread":"3.66"},{"groupId":"OG003","value":"-3.6","spread":"3.94"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":60},"commonTop":["Fall","Hallucination (pooled)","Hallucination, visual","Edema peripheral","Constipation"]}}}